Skip to content
Screener

Rapport Therapeutics, Inc. RAPP Cash & Equivalents

Cash & Equivalents at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$8.72B-30.8%
Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
$186.32M+60.8%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$119.53M-11.7%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$474.76M+201%
Biohaven logo
BiohavenBHVN
$277.11M+170%
Septerna, Inc. logo
Septerna, Inc.SEPN
$71.61M-65.9%

Other financials

Income statement

See full
Revenue-—
Operating income-$60.8M-106%
Net income-$56.6M-112%
EPS (diluted)-$1.19-58.7%

Balance sheet

See full
Total debt$10.1M-14.8%
Total equity$422.9M+60.5%
Total assets$459.0M+60.8%

Cash flow

See full
Operating cash flow-$41.5M-65.4%
CapEx$78.0K+255%
Free cash flow-$41.5M-65.5%

Valuation

See full
Market cap$2.22B+317%
Enterprise value$2.17B+343%
P/S111.2×—

Profitability

See full
Operating margin-767.6%—
Net margin-685.8%—
FCF margin-485.7%—

Returns & leverage

See full
Return on equity-40%+22.3pp
Debt / equity0×0.0×
Current ratio15.7×-7.0×

Where this comes from

Reported directly by Rapport Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 7:30 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333862
Line itemJune 30,2026December 31,2025
Assets
Current assets
Cash and cash equivalents$63,612$52,645
Accounts receivable293—
Short-term investments372,465437,894
Restricted cash105105
Prepaid expenses and other current assets10,3817,917
Total current assets446,856498,561

Item 1. Financial Statements.

FAQ

What is Rapport Therapeutics, Inc.'s cash & equivalents?
Rapport Therapeutics, Inc. (RAPP) reported cash & equivalents of $63.61M in Q2 2026.
How has Rapport Therapeutics, Inc.'s cash & equivalents changed year-over-year?
Rapport Therapeutics, Inc.'s cash & equivalents increased by 15.5% year-over-year, from $55.07M to $63.61M.
What is the long-term trend for Rapport Therapeutics, Inc.'s cash & equivalents?
Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s cash & equivalents has grown at a -13.4% compound annual growth rate (CAGR), from $70.17M to $52.65M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Rapport Therapeutics, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude